Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score

Table 2 Patient demographics between two groups in HCC patients

	Operation	Ablation	P-value
	(n = 226)	(n = 52)
Age (yr)	60.2 ± 10.5	58.3 ± 10.7	0.074
Gender
male/female	179/43	37/15	0.283
Time to treatment (yr)1	(5.1, 8.4, 11.2)	(5.4, 9.3, 11.6)	0.28
Background liver
chronic hepatitis/cirrhosis/normal	119/94/13	4/48/0	< 0.001
Hepatitis virus
B/C/B&C/non-B non-C	72/116/11/27	11/36/5/0	0.007
Child-Pugh classification
A/B	201/25	34/18	< 0.001
Pretreatment
Yes/No	78/148	0/52	< 0.001
Tumor size
< 5 cm/≥ 5 cm	160/66	49/3	< 0.001
Number of tumors
solitary/multiple	174/52	37/15	0.479
Vascular involvement
No/Yes	162/64	48/4	0.003
Adjuvant therapy
Yes/No	5/221	0/52	0.615

¹Each triplet gives the 25^th, 50^th and 75^th sample percentiles. Time to the treatment since 1 January 1994.